The Egyptian International Pharmaceutical Industries Company (EIPICO) posted 4.46% year-on-year (YoY) higher consolidated net profits after tax attributable to the holding company in the first half (H1) of 2025.

The Egyptian International Pharmaceutical Industries Company (EIPICO) announced the payment of cash dividends valued at EGP 3 per share for 2024.

The Egyptian International Pharmaceutical Industries Company (EIPICO) reported a 58.8% year-on-year (YoY) increase in consolidated net profit excluding minority interest for the first nine months of 2024.

The Egyptian International Pharmaceutical Industries Company (EIPICO) has announced plans to increase its authorized capital from EGP 1.5 billion to EGP 6 billion.

The Egyptian International Pharmaceutical Industries Company (EIPICO) reported a 58% year-on-year (YoY) increase in consolidated net profit excluding minority interest for the first half (H1) of 2024 to EGP 731.85 million from EGP 463.41 million.

The Egyptian International Pharmaceutical Industries Company (EIPICO) reported an 228.91% year-on-year (YoY) increase in consolidated net profit excluding minority interest for the first quarter (Q1) of 2024, according to the consolidated financial income statement filed to the Egyptian Exchange (EGX) on May 30th.

Egyptian International Pharmaceutical Industries Company (EIPICO) has approved the distribution of cash dividends of EGP 2 per share to shareholders for 2023.

The Egyptian International Pharmaceutical Industries Company (EIPICO) reported a 27.97% year-on-year (YoY) increase in consolidated net profit excluding minority interest for the first nine months of 2023, according to the financial income statement filed to the Egyptian Exchange (EGX) on February 29th.

Egyptian International Pharmaceutical Industries Co. (EIPICO) is aiming to achieve sales of more than EGP 6.5 billion this year

The Egyptian International Pharmaceutical Industries Company (EIPICO), in cooperation with the Arab Company for Drug Industries and Medical Appliances (ACDIMA) and the Suez Canal Economic Zone (SCZONE), has finished the incorporation procedures of the pharmaceuticals firm Arab API.

The Egyptian International Pharmaceutical Industries Company (EIPICO) reported a 50.6% year-on-year (YoY) increase in consolidated net profit excluding minority interest for the first nine months of 2023.

The Egyptian International Pharmaceutical Industries Company (EIPICO) is planning to get a loan of around $70 million from QNB Alahli and Banque du Caire to finance EIPICO 3 factory for the manufacturing of biopharmaceuticals and biosimilars, Chairman Ahmed Kelani said .

The Egyptian International Pharmaceutical Industries Company’s (EIPICO) board of directors has approved inviting senior shareholders to subscribe to the capital increase of Medical Union Pharmaceuticals (MUP).

The Egyptian International Pharmaceutical Industries Company (EIPICO) has denied receiving any offers to sell the main shareholder’s stake in the company to a strategic investor.

EIPICO is an Egypt-based public shareholding company that operates in the pharmaceutical industry. It is a manufacturer and exporter of pharmaceuticals and holds license agreements with a group of international.

The subscription to the Egyptian International Pharmaceutical Industries Company’s (EIPICO) capital increase was 86.21 times covered in the second phase.

EIPICO is an Egypt-based public shareholding company that operates in the pharmaceutical industry. It is a manufacturer and exporter of pharmaceuticals and holds license agreements with a group of international.

Founded in 1980, EIPICO is an Egypt-based public shareholding company that operates in the pharmaceutical industry. It is a manufacturer and exporter of pharmaceuticals and holds license agreements with a group of international.

Egyptian International Pharmaceutical Industries Company’ (EIPICO) ordinary general assembly meeting (OGM) has approved the distribution of cash dividends of EGP 2 per share to shareholders for 2022.

EIPICO is an Egypt-based public shareholding company that operates in the pharmaceutical industry. It is a manufacturer and exporter of pharmaceuticals and holds license agreements with a group of international.